These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24800907)

  • 21. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment.
    Meyers JL; Candrilli SD; Kovacs B
    Postgrad Med; 2011 May; 123(3):133-43. PubMed ID: 21566423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe.
    Castelino RL; Peterson G
    Evid Based Med; 2016 Apr; 21(2):68. PubMed ID: 26786825
    [No Abstract]   [Full Text] [Related]  

  • 23. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hyperglycemia in patients with type 2 diabetes and cardiovascular disease].
    Madsbad S
    Ugeskr Laeger; 2016 Dec; 178(52):. PubMed ID: 28041545
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypertension in patients with type 2 diabetes.
    Weir MR
    Hosp Pract (1995); 2001 Jan; 36(1):41-2, 47-8, 51-4; discussion 54. PubMed ID: 11197942
    [No Abstract]   [Full Text] [Related]  

  • 26. Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
    Uzu T; Yokoyama H; Itoh H; Koya D; Nakagawa A; Nishizawa M; Maegawa H; Yokomaku Y; Araki S; Abiko A; Haneda M
    Clin Exp Nephrol; 2011 Feb; 15(1):58-63. PubMed ID: 20824296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The current aspects of the pharmacological correction of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (type 2)].
    Gorbenko NI
    Eksp Klin Farmakol; 1999; 62(5):71-8. PubMed ID: 10572759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycemic treatment in type 1 and type 2 diabetes.
    Bloomgarden ZT
    Diabetes Care; 2006 Nov; 29(11):2549-55. PubMed ID: 17065700
    [No Abstract]   [Full Text] [Related]  

  • 29. Dissonance among treatment algorithms for hyperglycemia in type 2 diabetes: an egalitarian dialog.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    J Endocrinol Invest; 2019 Feb; 42(2):237-242. PubMed ID: 29704235
    [No Abstract]   [Full Text] [Related]  

  • 30. [Diabetes treatment in patients with chronic kidney disease].
    Süfke S; Steinhoff J; Schütt M
    Dtsch Med Wochenschr; 2013 May; 138(21):1109-18; quiz 1119-22. PubMed ID: 23677506
    [No Abstract]   [Full Text] [Related]  

  • 31. Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.
    Fu EL; van Diepen M
    Diabetes Care; 2020 Nov; 43(11):e190. PubMed ID: 33082247
    [No Abstract]   [Full Text] [Related]  

  • 32. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 34. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.
    Górriz JL; Cos Claramunt FX; Duque N; Matali A
    Prim Care Diabetes; 2019 Dec; 13(6):485-494. PubMed ID: 31400992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.
    Kwon S; Kim CT; Lee JP
    Diabetes Care; 2020 Nov; 43(11):e191. PubMed ID: 33082248
    [No Abstract]   [Full Text] [Related]  

  • 36. The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association.
    Diabetes Care; 1995 Nov; 18(11):1510-8. PubMed ID: 8722084
    [No Abstract]   [Full Text] [Related]  

  • 37. Extent of glycemic control in type 2 diabetes mellitus: close, but no cigar.
    Lerch C; Richter B
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):593-5. PubMed ID: 19833492
    [No Abstract]   [Full Text] [Related]  

  • 38. [Diabetes type 2: does intensive glycaemic control provides advantages?].
    Jacob S
    Dtsch Med Wochenschr; 2014 Mar; 139(13):628. PubMed ID: 24648172
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of hyperglycemia in adult-onset diabetes mellitus].
    Yki-Järvinen H
    Duodecim; 1999; 115(10):1155-64. PubMed ID: 11877855
    [No Abstract]   [Full Text] [Related]  

  • 40. SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now.
    Taliercio JJ; Thomas G; Nakhoul GN; Vachharajani TJ; Mehdi A
    Cleve Clin J Med; 2021 Jan; 88(1):59-63. PubMed ID: 33384316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.